Are you Dr. Parasuraman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 25 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-8246Fax+1 617-730-0641
Summary
- Dr. Sudha Parasuraman, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts, New Hampshire, and California.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 1995 - 1998
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Pediatrics, 1994 - 1995
Children's Hospital of MichiganResidency, Pediatrics, 1992 - 1994
Kilpauk Medical CollegeClass of 1991
Certifications & Licensure
CA State Medical License 1994 - 2026
MA State Medical License 1998 - 2026
NH State Medical License 1998 - 2026
Clinical Trials
- Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme Start of enrollment: 2009 Jun 01
- A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome Start of enrollment: 2018 Jun 01
- Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Start of enrollment: 2019 Aug 01
Publications & Presentations
PubMed
- 65 citationsFunctional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcomaAlyssa L. Kennedy, Mounica Vallurupalli, Liying Chen, Brian D. Crompton, Glenn S. Cowley
Oncotarget. 2015-08-19 - 214 citationsA Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and LymphomasJeffrey R. Infante, P. A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh
Clinical Cancer Research. 2016-12-01 - 112 citationsA phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumorsBirgit Geoerger, Franck Bourdeaut, Steven G. DuBois, Matthias Fischer, James I. Geller
Clinical Cancer Research. 2017-05-15
Press Mentions
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-in-Class PARP7 InhibitorSeptember 4th, 2019
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business OfficerAugust 6th, 2019- X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of x4p-001-RD in Patients with WHIM SyndromeJune 15th, 2018
- Join now to see all
